Bluebird Bio: latest news - GoINPHARMA
Wednesday, 19 September 2018 - 12:32

Bluebird Bio

Analysts don’t approve of Celgene’s takeover to Juno Therapeutics

Analysts are assessing Celgene’s potential takeover to Juno. Despite their different views, all experts agree that the acquisition will be very expensive ($8-$10bn) and will not provide any short-term solution to Juno’s issues. Juno Therapeutics offers Celgene the opportunity to…

Massachusetts, the cradle of modern biotechnology

Massachusetts seems to be the place in the world with the highest excitement for novel biotechnology, and is very likely to have the most important cluster of companies focusing on the development of novel therapies. What follows are some examples…